Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

IJ Diel; Richard Greil; J Janssen; CW Kluike; B Behera; A Abbasi; A Seesaghur; M Kellner; C Jaeger; K Bjorklof; A Tomova; F Haslbauer

doi:10.1007/s00520-022-07333-7

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

IJ Diel
, Richard Greil (Co-author)
, J Janssen
, CW Kluike
, B Behera
, A Abbasi
, A Seesaghur
, M Kellner
, C Jaeger
, K Bjorklof
, A Tomova
, F Haslbauer

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

6 Citations (Web of Science)

Original language	English
Journal	SUPPORTIVE CARE IN CANCER
DOIs	https://doi.org/10.1007/s00520-022-07333-7
Publication status	Published - 2022

Keywords

BREAST-CANCER
MODIFYING AGENTS
DE-ESCALATION
RISK

Access to Document

10.1007/s00520-022-07333-7

Cite this

Diel, IJ., Greil, R., Janssen, J., Kluike, CW., Behera, B., Abbasi, A., Seesaghur, A., Kellner, M., Jaeger, C., Bjorklof, K., Tomova, A., & Haslbauer, F. (2022). Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. SUPPORTIVE CARE IN CANCER https://doi.org/10.1007/s00520-022-07333-7

Diel, IJ ; Greil, Richard ; Janssen, J et al. / Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. In: SUPPORTIVE CARE IN CANCER 2022.

@article{f02dce46cbf5471ab63d4c2b699f6806,

title = "Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study",

keywords = "BREAST-CANCER, MODIFYING AGENTS, DE-ESCALATION, RISK",

author = "IJ Diel and Richard Greil and J Janssen and CW Kluike and B Behera and A Abbasi and A Seesaghur and M Kellner and C Jaeger and K Bjorklof and A Tomova and F Haslbauer",

note = "Greil: Paracelsus Medizinische Privatuniversit{\"a}t, Salzburg, Austria",

year = "2022",

doi = "10.1007/s00520-022-07333-7",

language = "English",

journal = "SUPPORTIVE CARE IN CANCER ",

issn = "0941-4355",

publisher = "Springer Nature",

}

Diel, IJ, Greil, R, Janssen, J, Kluike, CW, Behera, B, Abbasi, A, Seesaghur, A, Kellner, M, Jaeger, C, Bjorklof, K, Tomova, A & Haslbauer, F 2022, 'Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study', SUPPORTIVE CARE IN CANCER https://doi.org/10.1007/s00520-022-07333-7

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. / Diel, IJ; Greil, Richard (Co-author); Janssen, J et al.
In: SUPPORTIVE CARE IN CANCER , 2022.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

AU - Diel, IJ

AU - Greil, Richard

AU - Janssen, J

AU - Kluike, CW

AU - Behera, B

AU - Abbasi, A

AU - Seesaghur, A

AU - Kellner, M

AU - Jaeger, C

AU - Bjorklof, K

AU - Tomova, A

AU - Haslbauer, F

N1 - Greil: Paracelsus Medizinische Privatuniversität, Salzburg, Austria

PY - 2022

Y1 - 2022

KW - BREAST-CANCER

KW - MODIFYING AGENTS

KW - DE-ESCALATION

KW - RISK

U2 - 10.1007/s00520-022-07333-7

DO - 10.1007/s00520-022-07333-7

M3 - Original Article

C2 - 36066628

SN - 0941-4355

JO - SUPPORTIVE CARE IN CANCER

JF - SUPPORTIVE CARE IN CANCER

ER -

Diel IJ, Greil R, Janssen J, Kluike CW, Behera B, Abbasi A et al. Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. SUPPORTIVE CARE IN CANCER . 2022. doi: 10.1007/s00520-022-07333-7